ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026

Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met-Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer.

John H Strickler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.